Mike Hannay is the Managing Director of MTIF.
Mike’s career spans both medicine and medical device development having led multi-national teams developing products such as Brilinta, Lynparza, Neupro Transdermal Delivery System, ProAir pressurised Metered Dose Inhaler (pMDI), Seroquel XR and Symbicort pMDI. After twenty five years in the pharmaceutical industry Mike led a European division of a large Contract Development and Manufacturing Organisation (CDMO) before joining the National Health Service in England to accelerate the spread of innovation to improve patient outcomes and stimulate economic growth. These experiences have built a passion for integrating development from “bench to bedside”.
The MTIF is an integral part of our mission to not only accelerate the development of innovative medical technologies that improve the lives of patients but also to stimulate economic growth in the East Midlands region. The investments in the creation of MTIF are building a unique ‘bench to bedside’ infrastructure for the rapid progression of medical technologies
Mike Hannay, Managing Director MTIF
Medical Technology Innovation and Adoption
Nottingham Universities provide help to enable more tests for COVID-19
Universities in Nottingham have today supplied 16 machines to support…
New magnetic resonance approach could identify high risk of pre-eclampsia
Scientists have developed a new magnetic resonance (MR) system which…